Anxious parents present their healthy 9-year-old son for evaluation of a slowly enlarging plaque that began developing on his lower back 3 months ago. What's the diagnosis?
The COVID-19 pandemic brings new questions every day. Questions about the disease itself are beginning to be answered, but questions about how medical practices need to change still remain. Contemporary Pediatrics will host a live 30-minute webinar on Thursday, April 9, 2020, at 6 PM, Eastern Daylight Time, to discuss the most pressing issues in Pediatrics during this pandemic.
The US Food and Drug Administration has approved ixekizumab (Taltz, Eli Lilly) injection, 80 mg/mL, for use in pediatric patients to treat moderate-to-severe plaque psoriasis. The approval means that the drug is the first interleukin 17A (IL-17A) agent available for use in pediatric patients.
Housing assistance programs are associated with lower emergency department (ED) use by children with asthma.
Second-generation antipsychotics (SGAs), used alone or with other psychotropic medications, are associated with metabolic disturbances, primarily weight gain and losses in triglyceride and high-density lipoprotein (HDL) values, a retrospective study in 128 youngsters showed. However, the changed values usually were within the normal reference values and often were not recognized.
Time spent with nature is a prescription for better physical and mental health. Families can encourage nature play at home both in the home and outdoors. Here are 6 ways to recreate some of the areas at the Gaffield Children’s Garden in Ann Arbor, Michigan, at home.
Notes in the electronic health record (EHR) have long been promoted as a way to keep patients involved in their care and to cut down on inquiries about what’s in the record. A new study shows that this promise is being kept.
Treatment regimens that include ondansetron as the antiemetic of choice for children who visit a pediatric emergency department for acute migraine are safe and effective, according to a retrospective review.
The US Food and Drug Administration has given approval for a supplemental new drug application for Eucrisa (crisaborole) that allows the nonsteroidal topical ointment to be used for treating mild-to-moderate atopic dermatitis (AD) in children aged as young as 3 months.
The American Academy of Pediatrics’ (American Academy of Pediatrics) newly issued recommendations for supervising the health care of children with Williams syndrome are based on a review of the current literature along with the consensus of physicians and psychologists with expertise in managing this condition, which is caused by a deletion of part of chromosome 7.